New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
10:00 EDTADBE, BSX, CVS, SPW, RJF, GFIG, DVA, TER, WBMD, R, MRO, HST, OFC, ESV, SNY, RDS.A, ITG, EVROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Adobe (ADBE) upgraded to Outperform from Underperform at JMP Securities... Corporate Office Properties (OFC) upgraded to Neutral from Sell at Citigroup... DaVita (DVA) upgraded to Buy from Neutral at Nomura... Evercore Partners (EVR) upgraded to Outperform from Market Perform at Keefe Bruyette... GFI Group (GFIG) upgraded to Outperform from Market Perform at Keefe Bruyette... Host Hotels (HST) upgraded to Buy from Neutral at Citigroup... ITG (ITG) upgraded to Outperform from Market Perform at Keefe Bruyette... Marathon Oil (MRO) upgraded to Buy from Neutral at Goldman... Raymond James (RJF) upgraded to Outperform from Market Perform at Keefe Bruyette... Royal Dutch Shell (RDS.A) upgraded to Outperform from Neutral at Credit Suisse... Ryder (R) upgraded to Top Pick from Outperform at RBC Capital... SPX Corp. (SPW) upgraded to Buy from Neutral at Nomura... Sanofi (SNY) upgraded to Buy from Hold at Jefferies... WebMD (WBMD) upgraded to Market Perform from Underperform at Raymond James... CVS Caremark (CVS) upgraded to Outperform from Neutral at Macquarie... Ensco (ESV) upgraded to Buy from Hold at Jefferies... Teradyne (TER) upgraded to Outperform from Sector Perform at Pacific Crest... Boston Scientific (BSX) upgraded to Overweight from Underweight at Barclays.
News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 18, 2015
07:09 EDTBSXBoston Scientific payment to J&J well below expectations, says Piper Jaffray
Subscribe for More Information
07:07 EDTSPWBarclays to hold a conference
Industrial Select Conference is being held in Miami on February 18-19.
06:50 EDTESVEnsco initiated with a Market Perform at BMO Capital
Subscribe for More Information
February 17, 2015
18:36 EDTBSXOn The Fly: After Hours Movers
Subscribe for More Information
16:29 EDTBSX Boston Scientific announces settltement of merger agreement lawsuit
Subscribe for More Information
16:09 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.73
Subscribe for More Information
16:08 EDTAAgilent sees Q2 EPS 37c-41c, consensus $39c
Subscribe for More Information
16:07 EDTAAgilent reports Q1 EPS 41c, consensus 41c
Subscribe for More Information
15:32 EDTANotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Devon Energy (DVN), consensus $1.05... Vornado Realty (VNO), consensus $1.23... Analog Devices (ADI), consensus 61c... FirstEnergy (FE), consensus 75c... CF Industries (CF), consensus $5.08... Agilent Technologies (A), consensus 41c... Cimarex Energy (XEC), consensus 82c... Flowserve (FLS), consensus $1.13... Fossil (FOSL), consensus $3.07... Rackspace (RAX), consensus 19c... Norwegian Cruise Line (NCLH), consensus 37c... Jack in the Box (JACK), consensus 87c... Cloud Peak Energy (CLD), consensus 7c... La-Z-Boy (LZB), consensus 38c... KAR Auction Services (KAR), consensus 29c... Owens & Minor (OMI), consensus 50c... Valmont Industries (VMI), consensus $1.65... Realty Income (O), consensus 66c.
11:38 EDTSNYGenzyme reports publication of ENGAGE registration study results
Subscribe for More Information
10:01 EDTCVSCVS says PCSK9 inhibitors could cost system $150B annually
Subscribe for More Information
February 16, 2015
15:17 EDTESVTransocean slashes dividend to 60c from $3.00, says CEO leaving
Subscribe for More Information
10:54 EDTADako and Ono Pharmaceutical announce collaboration
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer, NSCLC. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.
February 13, 2015
17:40 EDTSPWRelational Investors gives quarterly update on stakes
Subscribe for More Information
February 12, 2015
16:20 EDTSNYGenzyme announces data from Phase 1b study for Niemann-Pick Type B
Subscribe for More Information
11:34 EDTWBMDNeuberger Berman reports 5.53% passive stake in WebMD
08:52 EDTSNYSanofi's Genzyme reports Phase 3 results for Cerdelga
Genzyme, a Sanofi company, reported extension study data from its Phase 3 ENGAGE and ENCORE studies of Cerdelga, or eliglustat, a first-line oral therapy approved by the FDA and the European Commission for the treatment of certain adults with Gaucher disease type 1. Both extension studies demonstrated continued stability and/or improvements across established end points and published therapeutic treatment goals. ENGAGE is a phase 3, randomized, double-blind, placebo-controlled, multi-center tudy to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1. After 18 months, in the primary analysis period, improvements were seen across the following endpoints after 9 months on cerdelga: spleen size, platelet count, hemoglobin concentration, and liver volume. In the 9 month extension phase, patients who switched from placebo to eliglustat showed improvements similar to the eliglustat-treated patients during the primary analysis while the eliglustat-treated patients continued to show improvements during the 9 month extension period. There were no treatment-related discontinuations. ENCORE is a phase 3, randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients stabilized on enzyme replacement therapy. After 24-months, the study, which met the primary analysis criteria for non-inferiority to imiglucerase, had a composite endpoint of each of the following parameters: spleen volume, hemoglobin concentration, platelet counts, and liver volume at 12 months. During the 12-month extension period, the patients who crossed over to eliglustat treatment from imiglucerase remained stable. Patients treated with eliglustat for 24 months also maintained stability of clinical parameters during the extension period. The most common adverse reactions -- ≥10% -- in the primary analysis periods of ENGAGE and ENCORE were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain. In both extension studies the majority of adverse reactions with Cerdelga were mild and transient, and consistent with those in the primary analysis periods. Most patients in both of the Phase 3 studies continue to receive Cerdelga in longer term extension periods. The majority of patients are now in their 4th or 5th year of treatment.
08:42 EDTSPWSPX Corp. sees FY15 organic revenue growth 1%-4%
Subscribe for More Information
06:33 EDTSPWSPX Corp. sees FY15 revenue down 5% to down 1%
Subscribe for More Information
06:32 EDTSPWSPX Corp. reports Q4 adjusted EPS $2.36, consensus $2.21
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use